Table 4 lists the clinical parameters of these patients. Age, gender, location of tumour, histological grade, cT, cN, cM, and cStage did not correlate with PFTK1 expression. The response rate to chemotherapy was 50.6% for all cases. The response rate in PFTK1(+) was 27.9%, which was significantly lower than in PFTK1(−) patients (72.1%, P<0.001). A pathologically CR was observed in three PFTK1(−) cases. As shown in Supplementary Figure S3, PFTK1(+) patients had a significantly poorer prognosis with regard to OS and PFS (5-year OS: 32.5% vs 54.4%, P=0.042, 5-year PFS: 18.8% vs 52.7%, P=0.012). Here, CDK14 is linked to neoplasm.